Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.

Also called NCT03650556

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 224 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03650556
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03650556. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-28 (actual); primary completion 2020-12-21 (actual). Results posted on 2022-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
Condition
Persistent Atrial Fibrillation
Intervention (Device)
TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03650556
Content hash
88378101d1919d493db8bc1ef6debf2cc00d8de9165052ec51e2e85ccd20008d